News & Updates
Filter by Specialty:
COVID-19 jabs help reduce long-term symptoms
COVID-19 vaccination appears to reduce the odds of long COVID symptoms, with continuous improvement following a second dose, at least in the first few months after the shot, suggests a study.
COVID-19 jabs help reduce long-term symptoms
27 May 2022
Long COVID: What factors contribute to the risk?
Only a minority of patients are considered fully recovered 1 year after being discharged from hospital due to COVID-19, with women and obese individuals at increased risk of long COVID, according to results of the prospective PHOSP-COVID* study presented at ECCMID 2022 and published in The Lancet.
Long COVID: What factors contribute to the risk?
25 May 2022
What is the most preferred first-line agent for paediatric alopecia areata?
In the treatment of paediatric alopecia areata (AA), an autoimmune, nonscarring hair loss disorder with a variable disease course and significant psychosocial impact, the most preferred first-line agent is topical corticosteroids, followed by contact immunotherapy, according to a study.
What is the most preferred first-line agent for paediatric alopecia areata?
25 May 2022
OMDI shows potential as first-line treatment for glaucoma in real-world trial
In a retrospective review of real-world data from Japan, omidenepag isopropyl 0.002% ophthalmic solution (OMDI) demonstrated an intraocular pressure (IOP)-lowering effect in eyes with different types of glaucoma, without severe or serious adverse effects.
OMDI shows potential as first-line treatment for glaucoma in real-world trial
24 May 2022
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.